The firm says its Olerup QType test is available on both Roche and Applied Biosystems platforms.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
A King's College London-led team performed a genome-wide association study of kidney transplant donors and recipients.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.
Investigators characterized expression activity in kidney grafts from a group of transplant recipients who remained rejection-free without immunosuppression.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
At the recent IDWeek conference, company collaborators presented early validation data on a blood-based assay for cell-free microbial DNA.
The researchers plan to evaluate cfDNA and single cells isolated from the urine of patients who have had kidney transplants to identify signs of graft failure.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.
Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.